Annals
Established in 1927 by the American College of Physicians
:
Advanced search
A more recent version of this article appeared on July 4, 2006.
box Article
 arrow  Full Text of this article Free
space
 arrow  PDF of this article
(PDFs free after 6 months)
space
All Versions of this Article:
  arrow 145/1/35 (most recent)
  arrow 0000605-200607040-00129v1
 arrow  Figures/Tables List
space
box Services
 arrow  Send comment/rapid response letter
space
 arrow  Notify a friend about this article
space
 arrow  Alert me when this article is cited
space
 arrow  Add to Personal Archive
space
 arrow  Download to Citation Manager
space
 arrow  ACP Search                        
space
 arrow  Get Permissions
space
box Google Scholar
 arrow  Search for Related Content
space
box PubMed
Articles in PubMed by Author:
  arrow  Lloyd-Jones, D. M.
space
  arrow  Greenland, P.
space
 arrow  Related Articles in PubMed
space
 arrow  PubMed Citation
space
 arrow  PubMed
space

REVIEW

Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease

right arrow Donald M. Lloyd-Jones, MD, ScM; Kiang Liu, PhD; Lu Tian, ScD; and Philip Greenland, MD

4 July 2006 | Volume 145 Issue 1

Some experts propose C-reactive protein (CRP) as a screening tool for prediction of cardiovascular disease (CVD). Many epidemiologic studies show positive associations between elevated CRP levels and incident CVD. Assessment of the value of new prognostic tests, however, must rely on understanding of test characteristics rather than on associations measured by relative risks. In the case of CRP, test characteristics must be judged in the context of currently available CVD risk prediction algorithms. In this review of literature published before January 2006, the authors describe what is known about the additional utility of CRP in risk prediction. They find no definitive evidence that, for most individuals, CRP adds substantial predictive value above that provided by risk estimation using traditional risk factors for CVD. Use of CRP may add to risk estimation in a limited subset of individuals who are at intermediate predicted risk according to the Framingham risk score. The authors propose that many questions still must be addressed before CRP is incorporated into risk prediction algorithms and before universal screening with CRP can be recommended.

Author and Article Information
space

From Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

See also: The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women by N.R. Cook, J.E. Buring, and P.M. Ridker and C-Reactive Protein and Cardiovascular Disease Risk: Still an Unknown Quantity? by G. Davey Smith, N. Timpson, and D.A. Lawlor.

Potential Financial Conflicts of Interest: None disclosed.

Requests for Single Reprints: Donald M. Lloyd-Jones, MD, ScM, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611; e-mail, dlj{at}northwestern.edu.

Current Author Addresses: Drs. Lloyd-Jones, Liu, Tian, and Greenland: Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, 680 North Lake Shore Drive, Suite 1102, Chicago, IL 60611.







 Home | Current Issue | Past Issues | In the Clinic | ACP Journal Club | CME | Collections | Audio/Video | Mobile | Subscribe | Tools | Help | ACP Online 

Copyright © 2006 by the American College of Physicians.